A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis
- Conditions
- ight Chain (AL) Amyloidosisrare blood disease - heart failure
- Registration Number
- NL-OMON44130
- Lead Sponsor
- Prothena Therapeutics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Subjects must meet all of the following criteria:
1. Aged * 18 years
2. Newly diagnosed and AL amyloidosis treatment naïve
3. Bone marrow demonstrating clonal plasma cells
4. Confirmed diagnosis of AL amyloidosis by the following:
* Histochemical diagnosis of amyloidosis determined bypolarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance
AND
* Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis
5. Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following:
* Is black or African American
* Is over 75 years of age with concurrent monoclonal gammopathy
* Has a history of familial amyloidosis and has concurrent monoclonal gammopathy
OR
* If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsyproven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR)wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2
propanodicarboxylic acid (99mTc-DPD; Rapezzi 2011),hydroxymethylenediphosphonate (99mTc-HMDP; Galat 2015), or pyrophosphate (99mTc-PYP; Bokhari 2013) scintigraphy
6. Cardiac involvement as defined by all of the following:
* Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure
* Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole > 12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening
* NT-proBNP * 650 pg/mL and * 8500 pg/mL
7. Planned first-line chemotherapy contains bortezomib administered weekly and subcutaneously (SC)
8. Adequate bone marrow reserve, hepatic function, and renal function, as demonstrated by:
* Absolute neutrophil count (ANC) * 1.0 × 109/L
* Platelet count * 75 × 109/L
* Hemoglobin * 9 g/dL
* Total bilirubin * 2 times the upper limit of normal (× ULN)
* Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) * 3 × ULN
* Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) * 3 × ULN
Alkaline phosphatase (ALP) * 5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
* Estimated glomerular filtration rate (eGFR) * 30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI)
equation
9. Seated systolic blood pressure 90-180 mmHg
10. Distance walked during each Screening 6MWT
11. Women of childbearing potential (WOCBP) must have two negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception (Appendix 4) from Screening to 90 days following the last study drug administration
12. Male subjects must be surgically sterile or must agr
Subjects must meet none of the following criteria:
1. Non-AL amyloidosis
2. NT-proBNP < 650 pg/mL or > 8,500 pg/mL
3. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma (Appendix 5)
*Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis are potentially eligible upon approval of the Sponsor.
4. Subject is eligible for and plans to undergo ASCT or organ transplant
5. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject*s ability to safely receive treatment or complete study assessments
6. Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic (ECG) evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
7. Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease
8. ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:
* First degree AV-block
* Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
* Right or left bundle branch block
* Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., >110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or three representative beats if Lead II is not representative of the overall EKG])
9. Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 2 with pain, Grade 3, or Grade 4
10. Subject is receiving oral or IV antibiotics, antifungals or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents
11. Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1
12. Prior radiotherapy within 4 weeks of Month 1-Day 1
13. Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study
14. Active malignancy with the exception of any of the following:
* Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
* Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years
* Low-risk prostate cancer with Gleason score < 7 and prostate-specific antigen < 10 mg/mL
* Any other cancer from which the subject has been disease-free for * 2 years
15. History of severe allergy to any of the components of NEOD001 such as histidine/L histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 or history of Grade * 3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol)
16. Known or history of uncontrolled, active HIV, hepatitis B or hepatitis C infection
17. Prior treatment with plasma cell-directed chemotherapy, NEOD001, 11-1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid
18. Treatment with another investigational agent within 30 days of Month 1-Day 1
19. Women who are pregnant or lactating
20. Any condition which could interfere with, or th
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Time to all-cause mortality or cardiac hospitalization as adjudicated by the<br /><br>CEC</p><br>
- Secondary Outcome Measures
Name Time Method <p>* NT-proBNP best response from baseline to Month 9<br /><br>* Change from baseline to Month 9 in the Physical Component Score of the SF-36<br /><br>* Change from baseline to Month 9 in the 6MWT<br /><br>* For renal-evaluable subjects, renal best response from baseline to Month 9<br /><br>* For subjects with peripheral neuropathy due to AL amyloidosis, change from<br /><br>baseline to Month 9 in the NIS LL score<br /><br>* For hepatic-evaluable subjects, hepatic best response from baseline to Month<br /><br>9<br /><br>* Change from baseline to Month 9 in the KCCQ<br /><br>* Time to cardiac mortality or cardiac hospitalization as adjudicated by the CEC<br /><br>* Time to all-cause mortality</p><br>